Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-03 1:59 pm Purchase |
2024-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
MORGAN STANLEY MS |
3,828,810 5.400% |
3,828,810 (New Position) |
Filing History |
| 2024-11-14 7:53 pm Sale |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Point72 Asset Management, L.P. | 1,313,747 1.900% |
-1,362,949 (-50.92%) |
Filing History |
| 2024-11-14 6:43 pm Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
ORBIMED ADVISORS LLC | 2,925,900 4.200% |
2,925,900 (New Position) |
Filing History |
| 2024-11-14 4:05 pm Sale |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Commodore Capital LP | 3,410,384 4.800% |
-389,616 (-10.25%) |
Filing History |
| 2024-11-14 3:30 pm Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 6,603,996 9.400% |
4,048,000 (+158.37%) |
Filing History |
| 2024-11-14 1:22 pm Sale |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
PRICE T ROWE ASSOCIATES INC | 392,004 0.600% |
-2,166,476 (-84.68%) |
Filing History |
| 2024-11-14 09:01 am Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 6,880,527 9.900% |
3,746,131 (+119.52%) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
BLACKROCK INC BLK |
4,891,379 7.100% |
0 (Unchanged) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
BLACKROCK INC BLK |
4,891,379 7.100% |
2,804,816 (+134.42%) |
Filing History |
| 2024-07-10 06:47 am Sale |
2024-06-30 | 13G | C4 Therapeutics, Inc. CCCC |
STATE STREET CORP STT |
2,994,948 4.350% |
-4,158,332 (-58.13%) |
Filing History |
| 2024-04-10 09:52 am Purchase |
2024-03-31 | 13G | C4 Therapeutics, Inc. CCCC |
STATE STREET CORP STT |
7,153,280 10.430% |
7,153,280 (New Position) |
Filing History |
| 2024-03-08 1:11 pm Sale |
2024-03-08 | 13G | C4 Therapeutics, Inc. CCCC |
WASATCH ADVISORS INC | 5,516,718 8.000% |
-1,622,231 (-22.72%) |
Filing History |
| 2024-02-14 10:03 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
PRICE T ROWE ASSOCIATES INC | 2,558,480 5.200% |
-366,773 (-12.54%) |
Filing History |
| 2024-02-14 09:21 am Purchase |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,134,396 6.400% |
12,177 (+0.39%) |
Filing History |
| 2024-02-14 07:35 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
RTW Investments, LP | 0 0.000% |
-2,819,472 (Position Closed) |
Filing History |
| 2024-02-09 1:04 pm Purchase |
2024-02-09 | 13G | C4 Therapeutics, Inc. CCCC |
WASATCH ADVISORS INC | 7,138,949 14.500% |
1,363,251 (+23.60%) |
Filing History |
| 2024-02-05 10:24 am Purchase |
2024-01-26 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 2,555,996 5.200% |
720,000 (+39.22%) |
Filing History |
| 2024-02-02 09:34 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 1,835,996 3.700% |
-626,024 (-25.43%) |
Filing History |
| 2024-01-12 4:01 pm Purchase |
2024-01-04 | 13G | C4 Therapeutics, Inc. CCCC |
Betta Investment (Hong Kong) Ltd. | 5,567,928 8.100% |
5,567,928 (New Position) |
Filing History |
| 2024-01-04 4:15 pm Purchase |
2024-01-03 | 13G | C4 Therapeutics, Inc. CCCC |
Point72 Asset Management, L.P. | 2,676,696 5.400% |
2,676,696 (New Position) |
Filing History |